Skip to content
Screener

BridgeBio Pharma BBIO Shares (Diluted)

Shares (Diluted) at other companies

Pfizer logo
PfizerPFE
5.7B-0.1%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
165.4M-9.3%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
194.5M-1.3%
ALN
Alnylam PharmaceuticalsALNY
138.3M+5.9%
Celcuity logo
CelcuityCELC
54.5M+26.5%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
210.9M+11.8%

Other financials

Income statement

See full
Revenue$194.5M+66.8%
Gross profit$184.6M+61.9%
Operating income-$106.0M-1.5%
Net income-$166.6M+1.8%
EPS (diluted)-$0.84+4.5%

Balance sheet

See full
Cash & equivalents$882.0M+62.5%
Total debt$3.3B+32,101%
Total equity-$2.3B-38.2%
Total assets$1.4B+55.5%

Cash flow

See full
Operating cash flow-$197.3M+1.0%
CapEx$69.0K
Free cash flow-$197.3M+0.9%

Valuation

See full
Market cap$16.06B+87.5%
Enterprise value$18.44B+136%
P/S27.7×-8.6×

Profitability

See full
Gross margin95.1%-0.2pp
Operating margin-90.5%-41.2pp
Net margin-125.9%-54.5pp
FCF margin-76.8%

Returns & leverage

See full
Return on equity-216.8%
Debt / equity
Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:31 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001743881-26-000019
Line itemThree Months Ended March 31, 20262025
Net loss from equity method investments(18,283)(15,556)
Other income, net4,2538,231
Total other expense, net(60,599)(65,236)
Net loss(166,555)(169,608)
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests2,5122,186
Net loss attributable to common stockholders of BridgeBio$(164,043)$(167,422)
Net loss per share attributable to common stockholders of BridgeBio, basic and diluted$(0.84)$(0.88)
Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, basic and diluted194,789,897190,145,253

Item 1. Financial Statements (Unaudited)

FAQ

What is BridgeBio Pharma's shares (diluted)?
BridgeBio Pharma (BBIO) reported shares (diluted) of 194.8M in Q1 2026.
How has BridgeBio Pharma's shares (diluted) changed year-over-year?
BridgeBio Pharma's shares (diluted) increased by 2.4% year-over-year, from 190.1M to 194.8M.
What is the long-term trend for BridgeBio Pharma's shares (diluted)?
Over 4 years (2021 to 2025), BridgeBio Pharma's shares (diluted) has grown at a 7.3% compound annual growth rate (CAGR), from 576.4M to 764M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about BridgeBio Pharma's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude